HLB Life Science Co Ltd
KOSDAQ:067630
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3 235
11 560
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
HLB Life Science Co Ltd
Net Income (Common)
HLB Life Science Co Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
HLB Life Science Co Ltd
KOSDAQ:067630
|
Net Income (Common)
-â‚©77.7B
|
CAGR 3-Years
-55%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
-26%
|
|
|
C
|
Chorokbaem Healthcare Co Ltd
KRX:118000
|
Net Income (Common)
â‚©9.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
W
|
WSI Co Ltd
KOSDAQ:299170
|
Net Income (Common)
â‚©1.3B
|
CAGR 3-Years
-43%
|
CAGR 5-Years
100%
|
CAGR 10-Years
N/A
|
|
|
W
|
Wonik Co Ltd
KOSDAQ:032940
|
Net Income (Common)
â‚©26.6B
|
CAGR 3-Years
11%
|
CAGR 5-Years
18%
|
CAGR 10-Years
48%
|
|
|
B
|
BlueMTec Co Ltd
KOSDAQ:439580
|
Net Income (Common)
-â‚©4.8B
|
CAGR 3-Years
15%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
HLB Life Science Co Ltd
Glance View
HLB Life Sciences Co., Ltd. engages in the provision of energy saving services. The company is headquartered in Hwaseong, Gyeonggi-Do. The company went IPO on 2008-11-25. Along with subsidiaries, the Company operates its business through four segments. The Pharmaceutical Distribution segment is involved in the sale of pharmaceuticals and raw materials through SHINWHAADVANCE.CO.LTD. The Energy Business segment is engaged in energy service company (ESCO) business. The company is equipped with equipments, assets and technical personnel to engage in energy saving investment business. The Bio Development segment is engaged in the development of extracorporeal circulation type bio space, hepatocyte treatment agents and hemostatic agents. The main products include anticancer drugs such as Tegatrabetan and Seclidemstat. The Other Business segment is involved in the investment of small business start-ups and venture businesses, as well as manufacturing and sale of light emitting diode (LED) products.
See Also
What is HLB Life Science Co Ltd's Net Income (Common)?
Net Income (Common)
-77.7B
KRW
Based on the financial report for Jun 30, 2025, HLB Life Science Co Ltd's Net Income (Common) amounts to -77.7B KRW.
What is HLB Life Science Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-26%
Over the last year, the Net Income (Common) growth was -744%. The average annual Net Income (Common) growth rates for HLB Life Science Co Ltd have been -55% over the past three years , -31% over the past five years , and -26% over the past ten years .